Is OpenAI Astra a Crushing Blow to Embodied Models? Seven Takes from Two Roundtables
After Astra's Debut, Do Embodied AI Companies Still Have a Moat?
Articles
A Conversation with Liu Zhenyun and Ma Yi at the Bund Conference
Salty jokes, sweet jokes.
Code Class · September | Which Dimension Is Your Thinking Trapped In?
This issue of Code Class features a book recommended by one of our MaHui CEOs.
ENCOS Raises Over RMB 300 Million in Series B, Evolving From Joint Modules to a Full Hardware Platform | Luzhou Shengmingli
First-pass yield above 97%, ready for large-scale robot delivery
Talking Embodied Artificial Intelligence with Yu Chen: Embrace the Bubble, but Manufacturing Must Eventually Do the Math | Yunqi Capital Insights X Tencent Technology
The truly slow and expensive variable is data accumulated bit by bit by people in the real world.
Weibang Zhendian Closes Nearly RMB 100 Million Series B Led by Dalton Venture to Advance Commercialization in Industrial Inspection, Clinical, and AI for Science | Dalton Venture News
Recently, **Zhejiang Weibang Zhendian Optoelectronic Technology Co., Ltd. (hereinafter: Weibang Zhendian) completed a nearly RMB 100 million Series B round, led by Dalton Venture with participation from IDG Capital**. The funds will primarily be used to advance the commercialization of its products in industrial inspection, clinical applications, AI for Science, and other fields. Prior to this, Weibang Zhendian had completed two funding rounds, with investors including Tao Capital, FreeS Fund, Founder Hesheng, Naton Capital, and SND Group.
We're Building a WeChat Membership Community for the Next Generation of AI Entrepreneurs
Be an Active Doer in the Age of AI
Curing Your To-Do Anxiety with the World's Lightest, Thinnest AI Wearable Screen | Linear Voice
Redefining the relationship between people and information.
Former HiSilicon Kunpeng GM and Horizon Robotics Chip President Chen Peng Founds Jiuwanli, Raising Over $100M with BlueRun Ventures Backing | BlueRun Ventures
Edge and On-Device Agentic AI: The Next Blue Ocean
Qiming Star | One-Time Treatment, Long-Term Benefit: BBM-H901's First National Prescription Filled, Hemophilia B Care Enters Gene Therapy Era
This milestone breakthrough not only marks the first domestically developed innovative gene therapy becoming available to hemophilia B patients in China, but also signals that treatment for the disease in the country has officially entered an entirely new era of gene therapy.